TerminatedPhase 3

Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation

Stopped: Difficulty in enrolling new patients

France65 participantsStarted 2009-01

Plain-language summary

The use of tacrolimus in the long term as part of the immunosuppressive regimen after transplantation is associated to complications such as chronic nephrotoxicity, impaired glucose metabolism (diabetes mellitus) and an increase of the incidence of neoplasia. The conversion from a tacrolimus based therapy to a sirolimus based therapy associated with mycophenolate mofetil could improve the incidence of such complications. The aim of this study is to assess the risk/benefit ratio of this switch performed in stable renal transplant recipient between 12 months and 36 months after transplantation. The incidence of a composite endpoint (worsening of GFR evaluated by MDRD formula, incidence of cancer and diabetes) will be assessed 24 months after conversion.

Who can participate

Age range18 Years – 76 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Recipient age ≥18 and ≤ 75 ans. * Patients having received a first or second renal transplant from a cadaveric or living related donor between 12 and 24 months prior the inclusion. * Peak panel reactive antibody (PRA) \< 30 % * Patients with a stable renal function during the 3 months prior to inclusion (variation of serum creatinine lower than 20 %) * Creatinine clearance ≥ 40 ml/mn/1.73 m26. * Patients receiving as a stable immunosuppressive treatment associating: Mycophenolate mofetil (MPA AUC \> 30 mg.h/L) and Tacrolimus with a trough level \> 4 ng/ml, with or without corticoids Exclusion Criteria: * Multiorgan recipients * Patients receiving cyclosporine * Pregnancy * Recipients of ABO incompatible graft * Use of other immunosuppressive drugs. * Historical peak reactive antibody ≥ 30 % * Past medical history of humoral rejection, 2 episodes of acute cellular rejection * Past medical history of sub-clinical rejection on routine allograft biopsy * Calculated creatinine clearance \< 40 ml/mn/1.73 m2 * 24h proteinuria \> 1 g/24H * Patients with severe diarrhea * HTLV1 or HIV positivity * Known hypersensitivity to tacrolimus, mycophenolate mofetil, or sirolimus. * Total white blood cells \< 2500/mm3 or hemoglobin \< 9 g/dl

What they're measuring

The incidence of a composite endpoint (worsening of GFR estimated with MDRD formula, incidence of cancer and incidence of post-transplant diabetes mellitus) will be assessed 24 months after conversion.

Timeframe: 24 months

Trial details

NCT IDNCT00811915

SponsorUniversity Hospital, Rouen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-12